What patient-oriented evidence supports the use of evolocumab and inclisiran?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18434413
Cited by: 0

Abstract

Evolocumab and inclisiran effectively lower LDL-C levels, with evolocumab demonstrating additional reduction in cardiovascular event risk and inclisiran showing a favorable safety profile.

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Antiplatelet Therapy and Cardiovascular Diseases Atherosclerosis and Cardiovascular Diseases

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
30 January 2026